78 results
8-K
EX-99.1
CNSP
Cns Pharmaceuticals Inc
1 Apr 24
Berubicin study enrollment completed; Topline data expected in first half of 2025
5:01pm
Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements include, without limitation, the Company's timing
8-K
EX-1.1
CNSP
Cns Pharmaceuticals Inc
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
, claims, damages and liabilities referred to above shall be deemed to include any legal or other fees and expenses incurred in defending any litigation
8-K
EX-10.1
CNSP
Cns Pharmaceuticals Inc
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made.
(m) Litigation. Except … Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation, or (d) in violation of FCPA or OFAC regulations.
4.9
424B4
CNSP
Cns Pharmaceuticals Inc
31 Jan 24
Prospectus supplement with pricing info
4:27pm
. In the past, many companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We … may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our
8-K
EX-99.1
k4ssqnnj
18 Dec 23
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy
8:36am
424B3
hcbr62 v3pvm
30 Nov 23
Prospectus supplement
5:20pm
8-K
EX-99.1
s858rdszj
15 Nov 23
Results of Operations and Financial Condition
8:00am
8-K
EX-99.1
vdy5qzsldqkja8okh99
14 Aug 23
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Continued rapid pace of enrollment with ~75% of expected patients now enrolled
9:25am
8-K
EX-99.1
wnh2c 442o9q1h56
15 May 23
CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides
8:36am